Revolution Medicines (RVMD) Net Margin (2019 - 2023)

Revolution Medicines' Net Margin history runs 5 years deep, the most recent figure standing at 21770.49% for Q4 2023.

• On a quarterly basis, Net Margin fell 2140175.0% year-over-year to 21770.49% in Q4 2023; TTM through Sep 2024 was 76423.32%, a 7515705.0% decrease from a year earlier, with the FY2023 full-year figure at 3768.28%, down 306533.0% from the prior year.
• Net Margin declined to 21770.49% in Q4 2023 per RVMD's latest filing, from 2570.55% in the prior quarter.
• Across five years, Net Margin topped out at 97.27% in Q1 2019 and bottomed at 21770.49% in Q4 2023.
• The 5-year median for Net Margin is 390.86% (2020), against an average of 1952.74%.
• Across the five-year window, Net Margin soared 262334 bps in 2022 and sank 2140175 bps in 2023, its largest moves.
• Year by year, Net Margin stood at 155.91% in 2019, then plunged by 151 bps to 390.86% in 2020, then slumped by 42 bps to 556.83% in 2021, then soared by 34 bps to 368.73% in 2022, then tumbled by 5804 bps to 21770.49% in 2023.
• Per Business Quant, the three latest RVMD Net Margin figures stand at 21770.49% (Q4 2023), 2570.55% (Q2 2023), and 970.89% (Q1 2023).